Glaukos

GLAUKOS CORP

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Expert,Woman,Asian,Female,People,Review,Data,Number,Costing,Managerial

News

Downgrades

Markets

Analyst Ratings

Trading Ideas

GKOS

RGLS

This Parsons Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday

FDA And CDC Involvement

Health Care

Movers

General

Glaukos&#39; Epioxa NDA for keratoconus is under FDA review, with a decision expected by October 2025. Phase 3 trials support its non-invasive treatment potential.

FDA Sets Decision Date For Glaukos&#39; Keratoconus Treatment Without The Need Of Surgery

Wall-Street-ai7-1

Market Summary

Sector ETFs

Broad U.S. Equity ETFs

Econ #s

Economics

ETFs

Real Estate

$BTC

$ETH

CELH

FANG

GLOB

MELI

REAL

RIVN

SMMT

All three major U.S. stock indices are down Friday as traders reacted to several sets of fresh data that raised concerns about the economic outlook. 

Consumer Sentiment Drops 10%, UnitedHealth Under Investigation: What&#39;s Driving Markets Friday?

Glaukos Corp

Press Releases

Glaukos Submits New Drug Application to U.S. FDA for Epioxa™

Glaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical Platform

Glaukos to Release Fourth Quarter and Full Year 2024 Financial Results after Market Close on February 20

Glaukos Announces Fourth Quarter and Full Year 2024 Financial Results

Glaukos Announces FDA Acceptance of NDA Submission for Epioxa™

RadiusXR and Glaukos Corporation Announce a New Collaboration With Topcon Healthcare, Inc. and the Launch of Inspire®: A Next-Generation Visual Field Solution

Glaukos to Release First Quarter 2025 Financial Results after Market Close on April 30

Glaukos Announces the Release of its 2024 Sustainability Report

Glaukos to Present Multiple Scientific Abstracts at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Glaukos Announces First Quarter 2025 Financial Results

Abbott Laboratories

Baxter Intl

Becton, Dickinson and Company Common Stock

Becton Dickinson

Boston Scientific Corporation Common Stock

Boston Scientific

DexCom

Edwards Lifesciences Corporation Common Stock

Edwards Lifesciences

GE HealthCare Technologies Inc. - Common Stock

GE HealthCare Techs

Globus Medical, Inc. Class A Common Stock

Globus Medical

Hologic

IDEXX Laboratories

Inspire Medical Systems, Inc. Common Stock

Inspire Medical Systems

iRhythm Technologies, Inc. - Common Stock

iRhythm Technologies

Intuitive Surgical

Integer Holdings Corporation Common Stock

Integer Holdings

Masimo

Medtronic

Penumbra

Koninklijke Philips N.V. NY Registry Shares

Koninklijke Philips

Insulet

ResMed

Smith & Nephew

Steris

Stryker

Teleflex

Zimmer Biomet Holdings, Inc. Common Stock

Zimmer Biomet Holdings

Morgan Stanley

Stephens & Co.

Stifel

Truist Securities

Wells Fargo

Comments

Glaukos

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell